Fabian Tenenbaum Net Worth

The estimated Net Worth of Fabian Tenenbaum is at least $1.42 Million dollars as of 21 May 2019. Mr. Tenenbaum owns over 5,000 units of Bellerophon Therapeutics Inc stock worth over $19,371 and over the last 9 years he sold BLPH stock worth over $0. In addition, he makes $1,400,000 as Chief Executive Officer, Chief Financial Officer, Chief Business Officer, and Director at Bellerophon Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Tenenbaum BLPH stock SEC Form 4 insiders trading

Fabian has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BLPH stock worth $3,000 on 21 May 2019.

The largest trade he's ever made was buying 5,000 units of Bellerophon Therapeutics Inc stock on 21 May 2019 worth over $3,000. On average, Fabian trades about 357 units every 0 days since 2016. As of 21 May 2019 he still owns at least 484,282 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Mr. Tenenbaum stock trades at the bottom of the page.

Fabian Tenenbaum biography

Fabian Tenenbaum serves as Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director of the Company. Mr. Tenenbaum joined us from Anterios, Inc. a clinical-stage biopharmaceutical company focused on the development of dermatology products, where he served as Chief Financial Officer and Chief Business Officer from October 2014 to February 2016. Prior to that, Mr. Tenenbaum served as Chief Executive Officer with Syneron Beauty from 2011 to October 2014, and Chief Financial Officer and Executive Vice President of Syneron Medical from May 2007 to 2011. Prior to Syneron Medical, Mr. Tenenbaum was Vice President Americas for Radiancy, Inc., from 2002 to 2006, and Director, Commercial Operations and Corporate Development at Sunlight Medical, Inc. from 1999 to 2002. Mr. Tenenbaum holds a Bachelor in Medicine (B.Md.) from Ben Gurion University, Israel and an MBA from Columbia Business School.

What is the salary of Fabian Tenenbaum?

As the Chief Executive Officer, Chief Financial Officer, Chief Business Officer, and Director of Bellerophon Therapeutics Inc, the total compensation of Fabian Tenenbaum at Bellerophon Therapeutics Inc is $1,400,000. There are no executives at Bellerophon Therapeutics Inc getting paid more.

How old is Fabian Tenenbaum?

Fabian Tenenbaum is 46, he's been the Chief Executive Officer, Chief Financial Officer, Chief Business Officer, and Director of Bellerophon Therapeutics Inc since 2016. There are 11 older and 6 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.

What's Fabian Tenenbaum's mailing address?

Fabian's mailing address filed with the SEC is 184 LIBERTY CORNER ROAD, SUITE 302, WARREN, NJ, 07059.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein, and Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.

What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Complete history of Mr. Tenenbaum stock trades at Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Fabian Tenenbaum,
  Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
• Peter Fernandes,
  Chief Regulatory and Safety Officer
• Assaf Korner,
  Chief Financial Officer, Secretary
• Peter Fernandes M. Pharm,
  Interim Principal Exec. Officer, Chief Regulatory & Safety Officer
• Martin Dekker,
  Vice President - Engineering and Manufacturing
• Jonathan Peacock,
  Chairman of the Board
• Crispin Teufel,
  Independent Director
• Mary Cloyd,
  Independent Director
• Naseem Amin,
  Independent Director
• Andre Moura,
  Independent Director
• Theodore Wang,
  Independent Director
• Scott Bruder,
  Independent Director
• Matthew Bennett,
  Independent Director
• Wassim Fares,
  Chief Medical Officer.
• Amy Edmonds,
  Vice President - Clinical Operations and Administration
• Parag Shah,
  Vice President - Business Operations
• Dr. Edwin L. Parsley,
  Acting Chief Medical Officer
• Dr. Parag Suresh Shah,
  VP of Bus. Operations
• Nicholas Laccona,
  Principal Financial & Accounting Officer and Sec.
• Cross Border Opportunities ...,
  
• Megan Schoeps,
  Principal Financial Officer
• Matthew S. Holt,
  Director
• Deborah Quinn,
  Chief Medical Officer
• Adam Weinstein,
  Director
• Daniel Tasse,
  Director
• Mountain Investments Ii, Ll...,
  
• Life Science Opportunities ...,
  
• Associates Iv L P Venrock M...,
  
• Associates Iv L P Venrock H...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Shah Nimi...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Venrock H...,
  
• Jens Luehring,
  Director
• Venture Fund Vi Lparch Vent...,
  
• Martin Meglasson,
  Chief Scientific Officer
• Mountain Investments Ii, Ll...,
  
• Manesh Naidu,
  Chief Business Officer
• Robert Nelsen,
  Director
• North America, Inc. Linde,
  10% owner
• Amit Agrawal,
  Chief Operating Officer
• David Abrams,
  Treasurer
• R Scott Huennekens,
  Director
• Reinilde Heyrman,
  Chief Clinical Dev. Officer
• Associates Iv L Pvenrock En...,
  
• Life Science Opportunities ...,
  
• Nicholas Laccona,
  FINANCIAL OFFICER, (PFO & PAO)
• Capital Management Lp Puiss...,
  
• Life Science Opportunities ...,
  
• Bobae Kim,
  VP Reg. Affairs & Quality